PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40632978,Consistency and Heterogeneity of Microsatellite Instability (MSI) Status in Paired Biopsy and Surgical Specimens of Colorectal Cancer: A Necessity for MSI Reassessment After Treatment?,2025-Jul,Yan Linghua; Wei Baoye; Liu Fei,"Shanghai Tongshu Biotech Co Ltd, Shanghai, China.; Shanghai Tongshu Biotech Co Ltd, Shanghai, China.; Shanghai Tongshu Biotech Co Ltd, Shanghai, China.",N/A
40624157,"Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma.",2025-Jul-07,Silverman Ian M; Johnson Adrienne; Meng Chenfeng; Schonhoft Joseph D; Zimmermann Michal; Ulanet Danielle; Kim Hyeyeon; Rimkunas Victoria; Koehler Maria,"Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, St-Laurent, QC, Canada.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, St-Laurent, QC, Canada.; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Repare Therapeutics, Cambridge, MA, USA.; Repare Therapeutics, Cambridge, MA, USA.; Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.; Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. tyap@mdanderson.org.",tyap@mdanderson.org
40611295,Joint inference of mutational signatures from indels and single-nucleotide substitutions reveals prognostic impact of DNA repair deficiencies.,2025-Jul-03,Supek Fran,"Biotech Research and Innovation Centre (BRIC), Faculty of Health and Medical Sciences, University of Copenhagen, Ole Maaløes Vej 5, 2200, Copenhagen, Denmark. fran.supek@bric.ku.dk.",fran.supek@bric.ku.dk
40605011,Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids.,2025-Jul-02,Caleiras Eduardo; Ruiz-Llorente Sergio; Justo Juan; Justo Juan; Guerrero Félix; Hevia Vital; Martín Raquel; Pérez-Rodriguez Francisco José; Tejerina Julia; Prieto Mario; Comune Paula,"Vivía Biotech, Madrid, Spain.",jgarciadonas@hmhospitales.com
40596624,Lavender Exosome-Like nanoparticles attenuate UVB-Induced Photoaging via miR166-Mediated inflammation and collagen regulation.,2025-Jul-01,Liu Fei; Su Le; Yang Suzhen,"Shandong Freda Biotech Co., Ltd, 250101, Jinan, Shandong, China.; Shengsheng Xiangrong Biotechnology (Shandong) Co., Ltd, Jinan, P.R. China.; Shandong Freda Biotech Co., Ltd, 250101, Jinan, Shandong, China.",sdilizhaolin@163.com
40593569,Single-cell signaling network profiling during redox stress reveals dynamic redox regulation in immune cells.,2025-Jul-01,Ting Wen-Chieh; Sun Hsun-I; Huang Wei-Min; Tsai Pei-Ling; Tang Jih-Luh,"Retain Biotech, New Taipei City, Taiwan.; Retain Biotech, New Taipei City, Taiwan.; Retain Biotech, New Taipei City, Taiwan.; Retain Biotech, New Taipei City, Taiwan.; Department and Graduate Institute of Pharmacology, National Taiwan University, Taipei, Taiwan.; Retain Biotech, New Taipei City, Taiwan.",sychen@ibms.sinica.edu.tw
40589098,Impact of Molecular Tumor Board on Clinical Outcomes in Patients with Refractory Solid Tumor: a Real-World Study.,2025-Jul-01,Ding Jiang-Shui; Li Bing,"Burning Rock Biotech, Guangzhou,510300, China.",N/A
